[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499053":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Second Xiangya Hospital of Central South University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy",null,[12],"Diagnostic Test: WES and ctDNA detection",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST","WES and ctDNA detection",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Yan Hu, M.D., Ph.D.","CONTACT","8685296122","yanhu@csu.edu.cn",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China","RECRUITING","Changsha","Hunan","410011","China","CN",{"type":34,"coordinates":35},"Point",[36,37],112.97087,28.19874,{"lat":37,"lon":36},[40],{"name":20,"role":21,"phone":10,"phoneExt":10,"email":23},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Liu Wenliang","Professor",[46],{"name":47,"class":48},"Shanghai OrigiMed Co., Ltd.","UNKNOWN","100499053","the-role-of-ctdna-testing-plus-ai-based-pathology-in-resectable-lscc-100499053",false,"NCT05778253","The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC","Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)","Inclusion Criteria:\n\n* Histopathology or cytology confirmed the lung squamous cell carcinoma\n* Age ranging from 18 to 75\n* Agree to participate in this study and sign an informed consent form\n* Treatment-naive tumor\n* According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor\n* Sufficient tissue\u002Fblood samples are available to meet research requirements\n* The ECOG PS score is 0-1\n\nExclusion Criteria:\n\n* Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form\n* Non-squamous NSCLC\n* Unresectable IIIa-IIIb tumor\n* Patients with solid organ or blood system transplantation\n* Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors\n* Patients with interstitial lung disease\n* Patients with acute or chronic infectious disease\n* Pregnant and lactating women\n* Patients who have undergone other clinical drug trials","ALL","18 Years","75 Years",{"count":60,"type":61},50,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.",[65],"Lung Squamous Cell Carcinoma","2023-03-18",{"date":68,"type":69},"2023-03-21","ACTUAL",{"date":71,"type":61},"2023-03-23",{"date":73,"type":61},"2029-09-23",{"name":5,"class":6},1]